A Clinical Trial of Adjunctive Thyroxine for Avolition in Schizophrenia
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Antipsychotics plus Levothyroxine Sodium, Antipsychotics plus Placebo.
- Who it may be relevant to
- Registry conditions: Schizophrenia, Avolition. Basic parameters: 18 years — 45 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The goal of this clinical trial is to investigate whether adjunctive thyroxine treatment can ameliorate motivation deficits in adults with schizophrenia experiencing predominant avolition (core negative symptom). The main questions it aims to answer are: * Does adjunctive thyroxine reduce avolition symptoms compared to placebo? * Does adjunctive thyroxine normalize cortico-striatal circuit activity during reward processing? Researchers will compare the treatment group (adjunctive sodium tablets, 50μg/day) with the control group (dose-equivalent placebo starch tablet) to see if thyroid hormone: 1. Significantly improves clinical scores of avolition 2. Modulates neural activation in motivation-processing brain circuits Participants will: * Maintain stable antipsychotic therapy for 8 weeks * Receive daily levothyroxine/placebo tablets * Complete the following assessments pre-/post-treatment: * Clinical evaluations (PANSS, NSA, PSP) * MRI scans (resting-state, structural, fMRI during reward tasks) * Blood tests * Behavioral motivation tasks
Interventions
- Drug Antipsychotics plus Levothyroxine Sodium
Maintain the original antipsychotic regimen combined with levothyroxine sodium tablets (Euthyrox), 50 μg/day for 8 weeks. Manufacturer: Merck Serono Ltd. Levothyroxine Sodium Tablets should be administered as a single daily dose on an empty stomach, 30 minutes before breakfast, with sufficient liquid (e.g., half a glass of water). - Drug Antipsychotics plus Placebo
All participants maintain pre-study antipsychotic medication at stable doses. ADDITIONALLY, they receive a visually identical placebo tablet. Placebo characteristics \& Blinding guaranteet: Matches levothyroxine in appearance (size/color/coating), taste, and packaging. Active ingredien : starch tablet with no biological activity. Administration: Once daily in the morning under identical fasting conditions.
Primary outcome measures
- the score of Motivation subscale of the Negative Symptom Assessment (NSA-15) [Time frame: Baseline, 2-week follow-up, 4-week follow-up, 6-week follow-up, 8-week follow-up]
Secondary outcome measures (3)
- Motivational deficits(avolition) measured by N2 (Emotional Withdrawal) and N4 (Passive/Apathetic, Social Withdrawal) items in the Positive and Negative Syndrome Scale (PANSS). [Time frame: Baseline, 2-week follow-up, 4-week follow-up, 6-week follow-up, 8-week follow-up]
- Performance of the monetary incentive delay task (MID) [Time frame: baseline, 8-week follow-up]
- Performance of the Effort-Expenditure for Rewards Task (EEfRT) [Time frame: baseline, 8-week follow-up]
Eligibility criteria
Inclusion criteria
- Meet the diagnostic criteria for schizophrenia according to the International Classification of Diseases, 10th Revision (ICD-10) (World Health Organization, 1993);
- Aged between 18 and 45 years, right-handed;
- Currently clinically stable, with the primary antipsychotic medication formulation and dosage unchanged for at least 4 weeks, and a total PANSS score ≤ 60;
- Predominant avolition symptoms, defined as a score ≥ 16 on the Motivation subscale of the Negative Symptom Assessment (NSA-15) (Zhou et al., 2023), with fewer than 3 items scoring ≥ 4 and fewer than 2 items scoring ≥ 5 on the PANSS positive subscale (Rabinowitz et al., 2013);
- Receiving one or two second-generation antipsychotics (SGAs), with stable medication doses for at least 1 month;
- Willingness and ability to maintain stable medication doses throughout the trial period;
- Capacity to understand study procedures, cooperate with all testing requirements, and provide written informed consent.
Exclusion criteria
- Current treatment with clozapine or first-generation antipsychotics;
- Current use of thyroid hormone medications or presence of thyroid dysfunction;
- Hypersensitivity to levothyroxine sodium; or history of non-hypothyroid-related heart failure, tachyarrhythmias, or recent myocardial infarction;
- Current use of medications known to interact with levothyroxine sodium that may affect its efficacy or safety (e.g., antidiabetic drugs, coumarin derivatives);
- History of endocrinological or cardiovascular/cerebrovascular diseases;
- IQ < 80 assessed by the Chinese short-form Wechsler Adult Intelligence Scale (Gong, 1981);
- History of substance abuse or drug addiction;
- History of traumatic brain injury or neurological disorders;
- Receiving electroconvulsive therapy (ECT) within the last 3 months;
- Pregnancy, lactation, or planning pregnancy within the next 2 months (for female participants);
- Claustrophobia; implanted metal devices (e.g., prosthetic implants, pacemakers); or other contraindications to MRI scanning.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07011953 · 2025-06-02